6533b82cfe1ef96bd1290775

RESEARCH PRODUCT

Management of Antiaggregated and Anticoagulated Patients Scheduled for Thoracic Surgery: Recommendations for Venous Thromboprophylaxis

Juan V. LlauMª José JiménezM. Granell

subject

medicine.medical_specialtybusiness.industrymedicine.drug_classmedicine.medical_treatmentAnticoagulantPercutaneous coronary interventionHeparinmedicine.diseaseThrombosisMechanical heart-valveSurgeryCardiothoracic surgerymedicineStent implantationAnticoagulant AgentIntensive care medicinebusinessmedicine.drug

description

The management of patients under the effect of antiplatelet or anticoagulant agents is a common challenge in thoracic surgery. Their temporary interruption or continuation needs a balanced assessment between the risk of thrombosis (interruption) and bleeding (continuation). Moreover, most patients must receive an anticoagulant for thromboprophylaxis (mainly a low-molecular-weight heparin). So, it is important to have in mind all surgical and anaesthetic implications of these drugs to take the optimal decision in each case.

yearjournalcountryeditionlanguage
2017-01-01
https://doi.org/10.1007/978-3-319-19908-5_16